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POLYCYSTIC OVARY SYNDROME: ROLE OF ANDROGEN EXCESS SELF-
ASSESSMENT IN DIAGNOSIS 
PASCALINE WANJIRU KARANJA 
ABSTRACT  
Background: Polycystic ovary syndrome is the most common endocrine disorder 
affecting reproductive-aged women. It is diagnosed using a combination of menstrual 
irregularity, clinical and/or biochemical hyperandrogenism and polycystic ovary 
morphology upon ultrasound. Hyperandrogenism in females may clinically manifest as 
hirsutism, acne, alopecia, or other masculinization of features. Assessing total/free 
testosterone, dehydroepiandrosterone sulfate, and 17-hydroxyprogesterone provides 
biochemical evidence of hyperandrogenism. 
Objective: To determine self-reported clinical signs of androgen excess using data from 
the Ovulation and Menstruation Health (OM) Study, a diverse, multi-ethnic cohort study 
being conducted at Boston University School of Medicine. 
Methods: Data was collected from participants enrolled in the Ovulation and 
Menstruation Health Study pilot cohort. This epidemiologic survey captured 
demographics, menstrual cycle patterns, PCOS histories, reproductive histories and 
manifestations of androgen excess in a diverse patient population. Participants were 
women ages 18-45 who had the capacity to ovulate/menstruate at the time of the study, 
had no history of chemotherapy, radiation, or surgical menopause, and were not pregnant 
at the time of the study. To assess androgen excess, participants were asked to self-report 
hair growth in nine body areas, acne on the face and back and hair loss on the scalp. The 
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nine body areas were scored using the modified Ferriman-Gallwey (mFG) scoring 
system. Reference images created by a medical illustrator were used for hirsutism and 
alopecia grading while clear descriptions were provided for grading acne severity. 
Clinical hirsutism was defined as total mFG score of ≥ 8, or ethnic specific cutoff for 
East Asian (≥ 2) and Southeast Asian (≥ 3) women. Alopecia was defined as scalp hair 
loss ≥ 2.  For participants that consented to medical record validation total, free and 
bioavailable testosterone lab levels were assessed for biochemical hyperandrogenism 
evaluation. 
Results: Beginning August 9, the day the study opened to the public, 249 participants 
completed the pilot survey questionnaire. These participants were 66.8% white (n=165), 
6.5% Hispanic or Spanish origin (n=16), 10.5% Black or African-American (n=26), 1.6% 
East Asian (n=4), 2.0% Southeast Asian (n=5), 2.4% South Asian (n=6), and 10.9% were 
of mixed ethnic backgrounds (n=27).  22.5% (55/245) of these women had clinical 
hirsutism by total mFG score. Mean total mFG scores were highest in women who were 
South Asian at 13.8±9.1 (n=6) and Hispanic at 8.6±8.7 (n=16). Moderate-severe acne 
was reported in 23.6% (58/246) of respondents, 24.8% (41/165) of white women, 26.7% 
(4/15) of Hispanic women, 15.4% (4/26) of Black women, 0.0% (0/4) of East Asian 
women, 20.0% (1/5) of Southeast Asian women, 50% of South Asian women (3/6) and 
20% (5/25) of women of mixed ethnicities. 9.4% (23/246) of all pilot women reported 
alopecia, highest in Black (26.9%, 7/26) and East Asian women (25%, 1/4). Among 
women that had a PCOS diagnosis there was a higher presence of clinical hirsutism, 
higher acne severity, and higher prevalence of alopecia when compared to non-PCOS 
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women. In addition, 33%(4/12) of the 44 women that consented to medical record 
validation had total testosterone levels above the normal range. 
Conclusions: This pilot population demonstrated an ethnic dependent pattern of 
development for hirsutism, acne and alopecia. Additionally, women who had a PCOS 
diagnosis were more likely to report having the clinical signs of androgen excess than 
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Polycystic Ovary Syndrome 
 Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine and 
metabolic disorders in reproductive-aged women. The etiology of PCOS is complex since 
both genetic variants and environmental factors play a role in its development (Azziz, 
2017). This disorder affects 6-10% of women globally, however its prevalence varies 
based on which diagnostic criteria is used when making the diagnosis (Azziz, 2017). 
There is also an increased prevalence of PCOS in women with oligoovulatory infertility, 
obesity and/or insulin resistance, either type of diabetes, first-degree relatives with PCOS, 
premature adrenarche history, use of antiepileptic drugs, and those of certain ethnicities 
(Azziz, 2017). The three diagnostic criteria most commonly used today are the NIH 
criteria developed in 1990, Rotterdam criteria developed in 2003, and the Androgen 
Excess and PCOS society (AE-PCOS) criteria developed in 2006 (Table 1)(Sirmans & 
Pate, 2013). The most current Guidelines by the Endocrine Society recommend the use of 
the Rotterdam Criteria for defining PCOS (Legro et al., 2013). This includes the 
diagnosis of at least two of the following: 1) clinical or biochemical hyperandrogenism, 
2) ovary dysfunction resulting in menstrual irregularity, or 3) polycystic ovary 







Table 1. Criteria for Polycystic Ovary Syndrome. Adapted from Sirmans & Pate, 2013 
1990 NIH Criteria 
(Include all of the following) 
2003 Rotterdam Criteria 
(Include 2 of the following) 
2006 AE-PCOS Criteria 
(Include all of the following) 





• Clinical and/or 
biochemical 
hyperandrogenism 
• Oligo-ovulation or 
anovulation 
• Polycystic ovaries 
• Clinical and/or 
biochemical 
hyperandrogenism 




 Patients qualify for a hyperandrogenism diagnosis if they have clinical 
manifestations and/or biochemical evidence of androgen excess. Hyperandrogenism can 
present clinically as hirsutism, acne, or alopecia, with hirsutism being the most 
commonly used clinical sign of androgen excess (Lizneva et al., 2016).  Biochemical 
evidence of hyperandrogenism, which is referred to as hyperandrogenemia, includes 
elevated serum androgen concentrations as determined by specific lab based thresholds 
(Lizneva et al., 2016). Most women with PCOS actually have both clinical signs and 
biochemical evidence of hyperandrogenism (Barbieri & Ehrmann, 2018a). Menstrual 
irregularity includes either infrequent ovulation (oligoovulation) causing menstrual 
patterns that consist of either less than 9 menstrual periods in a year or absent ovulation 
(anovulation) causing no menstrual periods for 3 or more consecutive months (Barbieri & 
Ehrmann, 2018a). Polycystic Ovary Morphology (PCOM) is the abnormal appearance of 
the ovaries upon ultrasound imaging. Despite the name, this abnormal appearance is 
determined based on follicular number and size, not cysts (Barbieri & Ehrmann, 2018a). 
 These clinical manifestations of PCOS do not only negatively impact the quality 
of life of the affected patients, but also cause a significant burden on society’s health care 
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resources (Tan et al., 2013). In 2005 the economic burden of PCOS in the United States 
(U.S.) was calculated to be approximately $4.37 billion annually (Azziz et al., 2005). 
This burden is largely associated with the increased prevalence of diabetes associated 
with PCOS (40%), hirsutism (14%), menstrual dysfunction treatments (31%), and use of 
infertility services (12%) (Azziz et al., 2005). Furthermore, the clinical manifestations of 
hyperandrogenism alone causes an economic burden estimated at more than $600 million 
in the U.S. annually (Bode et al., 2012). PCOS is also associated with other long-term 
health implications such as metabolic syndrome making it a significant public health 
concern.  
Long-term health outcomes associated with PCOS 
 There are various metabolic issues associated with PCOS. At least half of women 
with PCOS are also obese, which contributes to worse clinical manifestations of the 
disorder (Barbieri & Ehrmann, 2018c). Most women with PCOS also have insulin 
resistance or hyperinsulinemia, which can in turn contribute to hyperandrogenism both 
directly and indirectly (El Hayek et al., 2016; Barbieri & Ehrmann, 2018c). 
Hyperinsulinemia can stimulate androgen biosynthesis in the ovarian theca cell and can 
also have suppressive effects on SHBG production by the liver (Barbieri & Ehrmann, 
2018c). Women with PCOS also have a much higher prevalence of metabolic syndrome 
than the normal population (Sirmans & Pate, 2013). Additionally PCOS puts women at 
increased risk for nonalcoholic fatty liver disease, impaired glucose tolerance or type II 
diabetes, sleep apnea, mood disorders, and small dense LDL particles associated with 
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increased risk of coronary heart disease (Randeva et al., 2012). All these metabolic issues 
are risk factors for cardiovascular disease (Randeva et al., 2012).  
 Additionally, when women with PCOS conceive, either naturally or through 
ovulation induction therapy, the risk of pregnancy complications is increased (Qin et al., 
2013). These complications include early pregnancy loss, gestational diabetes mellitus 
(GDM), pregnancy induced hypertension, preeclampsia, and preterm birth (Qin et al., 
2013). For this reason it is important that women with PCOS receive proper screening 
and treatment interventions to either prevent the occurrence or properly manage these 
negative health outcomes (Legro et al., 2013; Sirmans & Pate, 2013). 
 
Clinical Manifestations of PCOS and their Diagnosis 
Hyperandrogenism  
 Hyperandrogenism is a common endocrine disorder with a prevalence of 5-10% 
in the general population (Yildiz, 2006). Clinical signs of hyperandrogenism may include 
hirsutism, acne, alopecia, and virilization in more severe cases (Yildiz, 2006). However, 
virilization is rare and often suggests an androgen-secreting tumor (Yildiz, 2006). 
Hyperandrogenism can present clinically without biochemical evidence of 
hyperandrogenemia and vice versa. Therefore either clinical manifestations or 
biochemical evidence of excess androgen can be used to diagnose hyperandrogenism 
(Yildiz, 2006). Additionally, patient history and physical examination are necessary for 






 Hirsutism is the most commonly used clinical diagnostic criteria for 
hyperandrogenism. About 80% of patients with hyperandrogenism also present with 
hirsutism (Yildiz, 2006).  It is prevalent in 7% of women in the general population and is 
marked by male-pattern excessive terminal hair growth (Yildiz, 2006). Male-pattern 
growth is deemed the appropriate terminology because men have higher androgen levels, 
and therefore higher degrees of terminal hair growth in sex-specific areas comparable 
with what is seen in these women. Androgens determine the type and distribution of hair 
growth and act on sex-specific areas of the body to convert the small, straight vellus hairs 
to long, coarse and thick terminal hairs (Bode et al., 2012; Yildiz, 2006). Therefore 
excess androgen causes excessive growth of terminal hairs in these areas (Bode et al., 
2012; Yildiz, 2006)(Figure 1). The most common cause of hirsutism is actually PCOS, 
accounting for 75% of hirsutism cases (Bode et al., 2012). Other causes of hirsutism 
include some androgenic medications and other endocrinopathies such as non-classic 
congenital adrenal hyperplasia, thyroid dysfunction, Cushing syndrome, acromegaly, 
hyperprolactinemia, androgen-secreting tumors, and neoplasms (Bode et al., 2012; 
Yildiz, 2006). However, the chance of neoplasm being the cause is rare as it only 
accounts for 0.2% of hirsutism cases. This form of hirsutism is often associated with 
rapid onset of symptoms, virilization, and palpable abdominal or pelvic mass (Bode et al., 
2012). Hirsutism may also arise spontaneously; 20% of hirsutism cases are caused by 
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idiopathic hyperandrogenemia associated with normal ovulation cycles and androgen 
excess. (Bode et al., 2012). 
 In addition to a physical examination, a medical and family history should be 
obtained to diagnose hirsutism (Bode et al., 2012). The physical examination includes an 
evaluation of the patient’s body hair to determine if the excess hair is terminal or vellus 
hair and whether it is growing in a male-pattern (Yildiz, 2006). The physician must also 
distinguish between hypertrichosis, which is excess hair growth all over the body that is 
not a result of hyperandrogenism. (Yildiz, 2006) Those determined to have a severe rapid 
onset of hirsutism should undergo further workup to eliminate or diagnose a possible 
androgen-secreting tumor (Bode et al., 2012). 
 The physical evaluation of hirsutism is most commonly done using the modified 
Ferriman-Gallwey (mFG) score. This is a pictorial scale that shows the distribution and 
degree of the hair growth. This subjective scale can either be used by the patient for self-
assessment or used by a clinician. The presence of hair growth in 9 androgen-sensitive 
body sites is scored on a scale of 0 to 4. These 9 areas are the upper lip, chin, chest, upper 
abdomen, lower abdomen, upper back, lower back, upper arms and thighs. A score of 0 
indicates an absence of terminal hair growth while a score of 4 indicates excessive 
terminal hair growth. An individual can have a total mFG score ranging from 0 to 36 
(Bode et al., 2012). Typically the cutoff for a hirsutism diagnosis is an mFG score of ≥8 
(Bode et al., 2012), however this cutoff may vary depending on ethnicity (Table 2). In 
summary, this mFG scoring system indicates that individuals with an mFG score less 
than 8 are considered normal, those with a score between 8 and 15 are considered to have 
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mild hirsutism and those with a score greater than 15 are considered to have moderate or 
severe hirsutism (Bode et al., 2012). 
Table 2. Ethnic specific Hirsutism Cut-offs. Summary of studies regarding ethnic 
specific cut-offs for mFG score. 
Ethnicity Suggested mFG cut-off Author, year 
Caucasian ≥8 DeUgarte et al., 2006 
Hispanic, Latina, or Spanish Origin  ≥8 DeUgarte et al., 2006 
Black or African American  ≥8 DeUgarte et al., 2006 
East Asian  ≥2 Yildiz et al., 2010 
Southeast Asian ≥3 Cheewadhanaraks, 2004 
South Asian  ≥6 Zargar, 2002 
 
Acne 
 Acne vulgaris is one of the most common visible skin disorders for individuals 
between the ages of 15 and 40 (Franik et al., 2018). Although acne is largely known to 
affect 70% of adolescents during puberty, it is important to note that adults are also 
affected (Franik et al., 2018; Gold et al., 2009).   It is prevalent in about 15% of all age 
groups (Uysal et al., 2017), with 4% being adult men and 13% being adult women (Tan 
et al., 2013). During puberty the increased adrenal androgen production is usually 
accompanied by increased acne severity, which suggests that acne is associated with 
increased androgen levels (Yildiz, 2006). Additionally, androgens cause sebaceous 
glands to enlarge increasing sebum production, black heads, and inflammation on the 
face, neck, chest, shoulders and back (Franik et al., 2018; Yildiz, 2006). Hormonal 
disorders, such as androgen excess, can cause increased acne severity and should 
therefore be evaluated (Uysal et al., 2017). This in turn explains the increased acne 




 Although there are many different methods for assessing the severity of acne, 
there is no universally agreed upon grading system. Most of these methods involve 
evaluating and counting the number, type and distribution of the lesions (Yildiz, 2006). 
The types of blackheads present, amount of inflammation, areas of the body affected and 
how widespread the acne is are all also evaluated when grading acne. The severity type is 
defined as mild, moderate, or severe (Pochi et al., 1990). Although there is no universally 
used acne global severity scale, diagnosis commonly occurs using clear descriptions of 
the different acne categories (Table 3) (Gold et al., 2009). 
 
Table 3. Types of Acne. Adapted from Gold et al., 2009 
Acne Type Description of Condition 
No acne Total absence of acne and blemishes 
Subclinical acne Small number of blackheads and whiteheads; barely visible; first sign 
of blemish 
Comedonal acne Blackheads and whiteheads (slightly inflamed—may be red); 
blemishes are visible 
Mild acne • Several inflamed pimples—red in color 
• Less than 20 whiteheads/blackheads or less than 15 inflammatory 
(red) lesions (pimples) or less than 30 total lesions (pimples) not 
all inflamed (red in appearance) 
Moderate Acne • Many inflamed pimples (red in color) and pustules (visible 
accumulation of pus in skin) 
• 20 to 100 whiteheads/blackheads or 15 to 50 inflammatory (red) 
lesions (pimples) or 30 to 125 total lesions (pimples) not all 
inflamed (red in appearance) 
Severe nodular acne • Inflamed pimples and pustules (visible accumulation of pus in 
skin) with a few deep nodular lesions (solid mass can be felt under 
skin—can sometimes be raised) 
• Greater than 5 cysts (solid mass of skin like a knot, can be raised 
or felt under the skin) or total whiteheads/blackheads count greater 
than 100 or total inflammatory count greater than 50 or greater 
than 125 total lesions 




 Alopecia is the loss of scalp hair and is also known as a male-pattern temporal 
form of balding (Yildiz, 2006; Barbieri & Ehrmann, 2018c).  Although there are several 
causes of alopecia, androgenic alopecia is the most common cause (Yildiz, 2006). 
Androgenic alopecia was reported in 67% of women with PCOS (Lizneva et al., 2016). 
Androgens can affect different stages of the hair follicle growth cycle and different areas 
of the body. This multi-component effect plays a role in determining whether hair growth 
or hair loss will occur. Although scalp follicles typically have the longest anagen phases, 
the phase that primarily determines the length of hair, increased androgen results in a 
shorter anagen phase (Randall, 2008) (Figure 1). This effect leads to hair loss by 
replacing the scalp’s thick, pigmented terminal hairs with smaller hair follicles and short 
non-pigmented vellus hairs (Yildiz, 2006) (Figure 2).  Androgenic alopecia is not 
commonly used as a marker of hyperandrogenism. However, if androgenic alopecia also 
presents with a history of irregular menses, hirsutism, acne, or virilization then an 
















Figure 2. Effect of Androgen on hair follicles (Adapted from Randall, 2008) Androgen 
stimulates hair growth in sex-specific areas, but has the opposite effect in scalp areas. 
 
Evaluation of alopecia includes conducting a hair-pull test to detect hairs in the 
telogen phase, examining for the presence of hirsutism or acne and assessing the hair loss 
pattern (Lizneva et al., 2016). The 3 common hair loss patterns are Ludwig’s type, 
Christmas tree, and Hamilton type (Herskovitz & Tosti, 2013). There are seven hair loss 
classification systems that have been proposed by various researchers for grading female 
pattern hair loss (Gupta & Mysore, 2016) (Table 4). The hair loss pattern is typically 
determined using the Ludwig scale or Christmas tree (Olsen) classification systems 
(Lizneva et al., 2016).  
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Table 4. Female pattern hair loss classification systems 
System Year and Source Description 
Ebling and Rook 
      
1975 
    Gupta & Mysore, 2016 
• 5-stage system 
• Centrifugal hair loss with 
recession of the 
frontotemporal hair line 
Ludwig System 1977 
     Ludwig, 1977 
• 3-stage system 
• Centrifugal hair loss while 
preserving the hair line 
Savin Scale 1992 
     Savin, 1992 
• 9 computer images 
• 8 stages of increasing 
crown balding and 1 
image for frontal anterior 
recession 
Olsen  1994 
     Olsen, 1994 
• Similar to Ludwig, but 
includes frontal-vertical 
alopecia (Christmas tree 
pattern) 
Bouhana* 2000 
     Bouhana, 2000 
• Multifactorial 
classification including 
extent of balding, degree 
of elasticity, thickness of 
the scalp, covering power 
of hair based on density, 
caliber, shape, length, 
growth rate, and hair color 
Sinclair 2004 
     Sinclair et al., 2004 
• Self-report photographic 
measure with 5 images 
• Images include hair parted 
centrally  
• Image 1 has no hair loss 
and severity of hair loss 
increases in the following 
images 
Basic and specific 
classification* 
2007 
     Lee et al., 2007 
• 4 Basic types represent 
shape of anterior hair line 
• 2 Specific types represent 
density of hair on frontal 
and vertex areas 
• Each type includes 
subtypes of severity 
• Combination of basic and 
specific types determines 
final type 





 Virilization is caused by an overproduction of androgens. It typically results from 
PCOS or a tumor. Virilization is characterized by androgenic alopecia, amenorrhea, 
deepening of the voice, increased muscle mass, decreased breast size, and clitoromegaly 
(Yildiz, 2006). Clitoromegaly is defined as a clitoral index greater than 35mm (Yildiz, 
2006).  Virilization may occur in patient’s experiencing severe or rapid 
hyperandrogenism. However, it is more commonly associated with an androgen-secreting 
neoplasm, particularly in cases of rapid onset of symptoms (Yildiz, 2006).  
Biochemical Hyperandrogenism 
 Androgens are hormones primarily produced in the adrenal glands and 
secondarily in the ovaries. These hormones include, but are not limited to, testosterone, 
dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), DHEA Sulfate (DHEA-S), 
and androstenedione.  
For individuals with moderate or severe hirsutism, biochemical tests for androgen 
excess are usually conducted (Bode et al., 2012).  Biochemical tests are done using a 
variety of assays to test for serum levels of total testosterone (TT), free testosterone (FT), 
androstenedione, and DHEA-S (Agapova et al., 2014).  Serum TT is the best estimate of 
androgen production in hirsute women (Martin et el., 2018).  Although plasma FT is 50% 
more sensitive than TT, it is expensive and not widely available (Bode et al., 2012). FT 
tests should only be considered if TT is only moderately elevated (Bode et al., 2012).  In 
women with hyperandrogenic symptoms but normal menstrual cycles, literature suggests 
measuring only TT levels (Barbieri & Ehrmann, 2018a).  For those with hyperandrogenic 
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symptoms and oligomenorrhea, serum TT, 17-hydroxyprogesterone (17OHP) and other 
routine labs should be run to identify the cause of the irregular menses (Barbieri & 
Ehrmann, 2018a). These tests are important since 22 to 85% of women with PCOS have 
elevated serum androgen levels (Azziz et al., 2009).  
 When measuring TT the normal limit is between 45-60 ng/dL (1.6 to 2.1 nmol/L), 
therefore a serum TT level above 60 ng/dL is elevated (Barbieri & Ehrmann, 2018a). If 
serum TT is over 150 ng/dL, an evaluation for causes such as adrenal-secreting tumors 
must be conducted due to this extremely high value (Barbieri & Ehrmann, 2018b). These 
reference values may depend upon the specific laboratory and methodology used. 
Women with PCOS, on the other hand, may present with either normal or elevated serum 
TT (The Rotterdam ESHRE/ASRM, 2004).  Special considerations must be made when 
measuring 17-OHP. This hormone must be measured in the morning, since levels are 
highest during this time, and within the early follicular phase for women that are still 
ovulating (Martin et al., 2018). For those without cycles, the latter consideration is not 
necessary and measurements can be taken at any point (Martin et al., 2018). This test is 
used to eliminate a nonclassic congenital adrenal hyperplasia (NCCAH) diagnosis since 
17-OHP levels greater than 200 ng/Dl suggest that the patient has NCCAH (Legro et al., 
2013). 
 In addition to biochemical tests, there are various assays to measure serum TT 
such as radioimmunoassays (RIAs), enzyme-linked immunosorbent assay (ELISA), 
chemiluminescence immunoassays (CLIAs) and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) (Rosner et al., 2007).  Although there is no standardized assay 
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to measure androgen in women, the Endocrine Society position statement suggests using 
LC-MS/MS, due to the fact that extraction and chromatography techniques increase 
sensitivity and accuracy as compared to direct immunoassays (Rosner et al., 2007; 
Agapova et al., 2014). 
Ovulatory Dysfunction 
 The most common cause of ovulatory dysfunction is PCOS (El Hayek et al., 
2016). Both oligoovulation and anovulation cause irregularities of the menstrual cycle 
resulting in either oligomenorrhea or amenorrhea, respectively (El Hayek et al., 2016; 
The Rotterdam ESHRE/ASRM, 2004).  These irregularities can manifest in a number of 
different ways. For example, there can be normal or slightly delayed puberty onset 
followed by irregular cycles, or menstrual cycles that are regular at first but then become 
irregular (Barbieri & Ehrmann, 2018c).  The infrequent ovulation makes it harder for 
women with PCOS to conceive or results in infertility if she experiences anovulation 
(Qin et al., 2013; Legro et al., 2013). 
Polycystic Ovary Morphology (PCOM) 
 The ultrasound appearance of PCOS can be evaluated noninvasively using high 
frequency transvaginal ultrasonography (Legro et al., 2013). The 2003 Rotterdam criteria 
defines PCOM as 12 or more follicles present in at least one ovary that are 2-9 mm in 
diameter and/or an ovarian volume greater than 10mL (The Rotterdam ESHRE/ASRM, 
2004). This criterion is also age-specific for women below 40 because follicle numbers 
and ovarian volume decrease with age (Barbieri & Ehrmann, 2018c).  It is unnecessary to 
perform this evaluation for PCOS diagnosis if a woman is already known to have 
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menstrual irregularity and hyperandrogenism (Barbieri & Ehrmann, 2018a).  The 
ultrasound should only be done if the woman has either hyperandrogenism, but 
borderline normal menstruation, or menstrual irregularity, but no evidence of 
hyperandrogenism (Barbieri & Ehrmann, 2018a). Figure 3 highlights the steps for PCOS 
diagnosis.  
Figure 3.  Flow Chart of Rotterdam Criteria to meet a PCOS diagnosis. 
 
Diagnostic Challenges of PCOS and Hyperandrogenism 
 There are certain challenges that come with diagnosing PCOS and its clinical 
manifestations. First, when diagnosing PCOS, physicians must be careful to eliminate 
other disorders that mimic the clinical features of this disorder, such as thyroid disease, 
hyperprolactinemia, and NCCAH (Legro et al., 2013). The diagnostic criterion also has 
age-specific limitations. In adolescents anovulatory symptoms and PCOM may be normal 
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in stages of reproductive maturation and not necessarily an indication of PCOS (Legro et 
al., 2013).  Therefore, PCOS diagnosis in adolescents should be based primarily on a 
hyperandrogenism diagnosis in the presence of persistent oligomenorrhea (Legro et al., 
2013).  In post-menopausal women, there is a normal presence of amenorrhea and 
decrease in follicle size further complicating the detection of PCOM (Barbieri & 
Ehrmann, 2018c).  Therefore, in post-menopausal women the Endocrine Society suggests 
using a well-documented history of amenorrhea and hyperandrogenism during their 
reproductive years to make a PCOS diagnosis (Legro et al., 2013). 
 When diagnosing hirsutism, there are limitations in using the mFG scale because 
it is subjective and doesn’t account for all androgenic areas. Furthermore, it does not take 
into consideration other possible causes of increased hair growth (Bode et al., 2012). 
When diagnosing hyperandrogenism, acne alone cannot be used. This is because most 
acne patients do not have hyperandrogenism and data regarding the prevalence of 
hyperandrogenism in acne patients is limited (Yildiz, 2006). However, if a patient has 
severe acne along with hirsutism or irregular menstrual periods then hyperandrogenism 
can be considered (Yildiz, 2006).  It is also important to keep in mind that measuring 
serum androgen levels is not useful for those on estrogen-progestin oral contraceptives, 
metformin, or spironolactone (Barbieri & Ehrmann, 2018a).  
 
Management and Treatment of PCOS 
 Early diagnosis and treatment are important for improving the quality of life for 
women with PCOS. However, most women report having a poor diagnostic experience 
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associated with long delays and inadequate health information (Barbieri & Ehrmann, 
2018a). Lifestyle interventions such as weight loss and decreasing the degree of insulin 
resistance, or hyperinsulinemia with diet, exercise or medications has decreased androgen 
levels in women (Barbieri & Ehrmann, 2018c; Legro et al., 2013).  Decreasing androgen 
levels improves some hyperandrogenic symptoms. Exercise, healthy diet and weight loss 
have been proven to reduce cardiovascular risk factors, diabetes, and reproductive 
dysfunction in the general population, and are thought to also work in improving these 
health outcomes in PCOS patients as well (Legro et al., 2013).  
Treatment of the hyperandrogenic, clinical manifestations of PCOS involves 
suppressing androgen production and/or action through the use of hormonal 
contraceptives, glucocorticoids, insulin-lowering agents and gonadotropin-releasing 
hormone agonists (GnRH) (Lizneva et al., 2016).   
Hormonal contraception is the first line of treatment for menstrual irregularity, 
hirsutism and acne (Legro et al., 2013).  In adolescents with PCOS, hormonal 
contraception, lifestyle therapy, and metformin, a drug that helps lower blood glucose 
levels, are the recommended treatment options (Legro et al., 2013). The Endocrine 
Society suggests metformin be used only in women who also have Type 2 Diabetes or 
impaired glucose tolerance and as a second line of therapy for women who have 
menstrual irregularity but cannot take or cannot tolerate hormonal contraception (Legro 
et al., 2013).  
To treat anovulatory infertility the Endocrine Society suggests the use of 
clomiphene citrate (Legro et al., 2013). This is a drug that stimulates the increase of 
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hormones that support ovulation. It should be used as the first-line treatment option with 
metformin as an adjuvant therapy to prevent ovarian hyperstimulation syndrome in PCOS 
patients undergoing in vitro fertilization (Legro et al., 2013).  
 Hirsutism treatment should be guided by the severity and the amount of distress it 
causes the patient (Bode et al., 2012).  If the symptoms are mild and menses are normal, 
then hirsutism can be treated based on a clinical educated guess (Bode et al., 2012).  If 
child bearing is not a current concern, then birth control should be the first line of 
treatment. Hormonal birth control is the best option as it increases sex hormone-binding 
globulin (SHBG), which therefore decreases the bioavailable testosterone levels and 
inhibits ovarian androgen production (Bode et al., 2012).  In addition to oral 
contraceptives, various medications commonly used for the treatment of hirsutism 
include antiandrogens, insulin-lowering agents and eflornithine. Topical agents such as 
eflornithine can also be used for excessive hair growth on the face (Bode et al., 2012). 
GnRH agonists are used only for severe cases that are not responsive to other treatment 
methods. Ketoconazole may also be used when other therapies have failed (Bode et al., 
2012).  Regardless of which treatment the patient chooses, it is important to monitor the 
response to the medication for 6 months before making adjustments (Bode et al., 2012). 
As an alternative to medication, a lot of women with hirsutism opt to use various methods 
for cosmetic hair removal. These methods include shaving, chemical depilation, waxing 
or plucking, electrolysis and laser therapy. Shaving is effective if repeated often, however 
it is only temporary and the hair regrown is coarser (Bode et al., 2012).  Chemical 
depilation can cause reactive dermatitis, waxing and plucking can cause scarring or 
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hyperpigmentation, electrolysis is only effective for smaller areas and laser therapy is 
expensive (Bode et al., 2012). 
 Acne treatments include both topical and systemic treatments (Lizneva et al., 
2016). For mild to moderate acne over the counter benzoyl peroxide preparations and 
topical cleansers can be used (Gold et al., 2009). For severe acne types, topical or 
systemic antibiotics provided by health care providers can be used (Gold et al., 2009). 
Additionally, phototherapy with blue light has been shown to improve skin conditions 
both in vivo and clinically, which can eliminate the need for prescriptions and harsh 
chemicals (Gold et al., 2009). These treatments can be used in addition to medications 
that decrease androgen levels. 
 Alopecia treatments are typically topical and usually contain 2% topical minoxidil 
(Lizneva et al., 2016). The treatment involves the application of 1ml minoxidil to the 
scalp twice daily for at least 12 months (Herskovitz & Tosti, 2013). These treatments are 
used in addition to medications to decrease androgen levels. If these treatments are not 
effective then patients can also choose additional cosmetic alternatives such as hair 





This thesis project seeks to determine self-reported clinical signs of androgen excess 
using data from the Ovulation and Menstruation Health (OM) Study, a diverse, multi-
ethnic cohort study being conducted at Boston University School of Medicine. 
Specifically, this thesis aims to: 
1. Describe the distribution of hirsutism within the Ovulation and Menstruation 
Health Study pilot cohort. 
2. Describe the distribution of acne within the Ovulation and Menstruation Health 
Study pilot cohort. 
3. Describe the distribution of alopecia within the Ovulation and Menstruation 







The Ovulation and Menstruation Health (OM) Study 
 The Ovulation and Menstruation Health (OM) Study is a comprehensive 
epidemiologic survey that seeks to characterize lifestyle and health characteristics of an 
ethnically diverse cohort of women. The study collects information regarding menstrual 
characteristics and manifestations of androgen excess in order to create a multi-ethnic 
longitudinal database to assess the health risks of PCOS. The goal of the pilot study 
specifically was to develop the best data collection methods and instruments for the 
future multi-ethnic, long-term PCOS cohort study that will be conducted in both English 
and Spanish. The recruitment goal for the pilot study was to have 200 participants 
complete the online consent form and survey module. A two-minute informational video 
on the menstrual cycle was created specifically for the OM Study and posted on the study 
website to be used for recruitment purposes. 
Survey Design 
 The pilot study consisted of an online baseline questionnaire designed by Dr. 
Shruthi Mahalingaiah, a board-certified reproductive endocrinology/infertility physician-
scientist at Boston University School of Medicine (BUSM). The survey was administered 
through REDCap, a secure web application for building and managing online research 
surveys and databases. The questionnaire collected information regarding demographics, 
anthropometrics, menstrual cycle health, contraceptive use, medication and supplement 
use, PCOS status, androgen excess characteristics, reproductive health, general health, 
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diet and lifestyle, and pregnancy and birth history. In addition, participants who have 
received care at Boston Medical Center (BMC) were given the option to have their 
survey results validated against their medical record. 
 A board-certified reproductive endocrinology/infertility physician-scientist 
designed the study questions. To ensure the survey questions were appropriate for a 
diverse population, particularly with respect to race/ethnicity and education level, the 
questions were written at an 8th grade reading level. Additionally, a select subset of 
questions underwent cognitive understandability and usability tests. To help participants 
correctly answer questions involving a self-reported rate of a condition, Renee Cannon, a 
licensed medical illustrator, was commissioned to sketch images for questions targeting 
body shape and hair growth.  
Study Population 
 The OM study pilot included women who were 18-45 years old that still had the 
capacity to ovulate and menstruate, no prior history of chemotherapy or radiation, and 
who were not currently pregnant. The study population was not recruited with 
consideration of a present PCOS diagnosis, which allowed both women with PCOS and 
non-PCOS controls to be captured. In order to be able to answer the questions, the study 
subjects were also required to be able to read English and have an email address for 
receiving the survey link. The pilot study population of the 249 participants who 
completed the entire survey was used to determine patterns of hirsutism, acne, and 






 Participants were actively recruited by multiple methods across multiple cities in 
the United States starting on August 9th, 2017. Although active recruitment for the pilot 
study ended October 10th 2017 the survey link is still currently open to additional 
participants. Initially the participants recruited were BMC patients who received a mailed 
letter prior to their appointment explaining the study and notifying them of the potential 
presence of study staff in their doctor’s waiting room. Upon arrival to the appointment, 
these patients were approached in the OB/GYN clinics in the BMC Doctor’s Office 
Building and Yawkey Clinic.  Additional participants were recruited in-person at a local 
community Women’s Market in Jamaica Plains, Boston, MA. The pilot recruitment then 
expanded to include the dissemination of the study website and survey link by posting 
flyers around Boston University and by advertisements on Facebook and other social-
networking and health-related websites.  
For in-person recruitment, the individuals were first asked to view an 
informational video about the study and were then asked to complete a screener if they 
were interested in participating. Eligible individuals were then prompted to start the 
survey on REDCap. For those that could not complete the survey in one sitting, follow-up 
emails were sent via REDCap. The emails provided participants with a code to access 
and proceed with their survey from the location they left off.  
Those accessing the survey online could also choose to watch the informational 
video on the study website before being directed to the screener and questionnaire. 
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Individuals who consented to participate in this pilot study were entered into a raffle for a 
$200 gift card that was awarded at the end of the pilot recruitment period. 
Hyperandrogenism analysis 
 In order to assess hyperandrogenism, questions from the survey measuring 
androgen excess indicators such as hirsutism, acne and alopecia were pulled from the 
dataset. Participants were asked to self-report the degree of hirsutism in nine androgen 
sensitive areas based on the images created by Renee Cannon (Figure 4). They were also 
asked to rate the severity of the acne based on a very brief description of the acne types 
(Table 5). Lastly, participants were asked to self-report degree of alopecia using the 
images illustrated by Renee Cannon (Figure 5).  
Assessments of patterns of the clinical manifestations were determined by looking 
at the frequencies of self-reported degree of hirsutism, acne and alopecia. Also of interest 
was the data for clinically captured biochemical androgen excess in the subset of women 












Figure 4. mFG Pictorial Tool.  Medical illustrator Renee Cannon illustrated these 
images for the OM Study. They were provided as the reference images to the questions 
asking women to self-report the degree of hirsutism.  
 
Table 5. Acne Type Descriptions These were the descriptors provided in the OM study 
questionnaire asking women to rate the severity of their acne. 
Acne Type Description 
None or rare acne None to a couple of pimples 
Mild acne 4 or more pimples 
Moderate acne 4 or more pimples that are red and irritated 





Figure 5. Alopecia Images Medical illustrator Renee Cannon drew these images based 
on the Sinclair classification system for the OM Study. They were provided as the 






 After 2 months of active recruitment, a total of 283 individuals were deemed 
eligible and started the survey, and 249 of these participants actually completed the 
survey (Table 6). The majority of participants that completed the survey were recruited 
online (45.4%). Out of the 247 women that completed the study survey and answered the 
race/ethnicity question, 66.8% were white, 6.5% were Hispanic or of Spanish origin, 
10.5% were Black or African-American, 1.6% were East Asian, 2.0% were Southeast 
Asian, 2.4% were South Asian, and 10.9% were of mixed ethnic backgrounds (Table 7). 
 
Table 6. Summary of Survey Completion The number of participants in the OM Study 
































Table 7. Cohort Study Population 
Characteristics Cohort 
Number of women 249 
Mean age (years) 27.1 yrs (n=249) 
White (%) 66.8%(165/247) 
Hispanic, Latina, or Spanish Origin (%) 6.5% (16/247) 
Black or African American (%) 10.5 (26/247)  
East Asian (%) 1.6% (4/247) 
Southeast Asian (%) 2.0% (5/247) 
South Asian (%) 2.4% (6/247) 
More than 1 race** 10.9% (27/247) 
Clinical hirsutism based on mFG score cutoff (%) 22.5% (55/245) 
Alopecia (scalp hair score >2) 9.35% (23/246) 
Acne (moderate-severe acne) 23.6 (58/246) 
PCOS diagnosis by physician (%) 23.1% (57/247) 
Any use of hormonal contraceptives (%) 84.3% (210/249) 
Permission granted for medical record validation (n)*  44/62 (71%) 
Androgen excess based on medical record review (n) 12/44 (27.3%) 
*Among women who answered they have received care at BMC 
 
Hirsutism 
 Clinical hirsutism was defined as total mFG score of ≥2 for East Asian women, 
≥3 for Southeast Asian women, or ≥8 in all other race/ethnic categories. These 
race/ethnic specific cutoffs for mFG scores were based on the currently available clinical 
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literature. Based on these cutoffs 22.5% of women in the study cohort met the criterion 
for a clinical hirsutism diagnosis. Furthermore, there was a higher presence of clinical 
hirsutism between South Asian (66.7%) and Hispanic (43.8%) women. Mean total mFG 
scores were also highest in South Asian (13.8±9.1) and Hispanic (8.6±8.7) women (Table 
9). Among women with PCOS the mean total mFG scores were higher (9.6 ± 7.6) than in 
non-PCOS women (3.7 ± 3.6). In addition there was a higher presence of clinical 
hirsutism among the population that had a PCOS Diagnosis (49.1%) when compared to 
non-PCOS women (14.7%) (Table 8). 
 
Table 8. PCOS Diagnosis and Androgen Excess clinical manifestations Both self-


















Yes 9.6 ± 7.6 49.1% 
(27/55) 
2.0 ± 1.0 33.9% 
(19/56) 
0.1 ± 0.4 14.3% (8/56) 
No 3.7 ± 3.6 14.7% 
(28/190) 
1.8 ± 0.9 20.5% 
(39/190) 





Table 9. Race/Ethnicity and Self-Reported mFG scores and Perception of Hairiness. 
Patients reported on hair growth using the mFG score (0 being absent hair growth, 4 being excess hair 
growth) based on references images provided with questionnaire. Race/ethnic cutoffs for mFG scores were 
used and specified based on current available clinical literature. Where information is conflicting the most 
commonly used cutoff or average of available cutoffs was utilize. Where primary data is unavailable, the 
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0 ± 0 0 ± 0 0.5±
1.0 
















































































 Mean population acne severity score (from 1 to 4) was 1.9 ± 0.9 (n=246).  
Moderate-severe acne was reported in 23.6%(58/246) of all surveyed women. Moderate- 
severe acne was also highest in South Asian Women (50%, 3/6) and lowest in East Asian 
women (0%) (Table 10). Women with PCOS (33.9%) had a higher prevalence of 
moderate-severe acne than non-PCOS (20.5%) women. Additionally women with a 
PCOS diagnosis had a higher acne severity mean (2.0 ± 1.0) than non-PCOS women (1.8 
± 0.9 (Table 8). 
Table 10. Race/Ethnicity and Self-Reported Acne Severity. Patients reported acne 
severity from scale of 1-4 (1 being none, 4 being severe) based on references images 
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 Alopecia was defined as moderate to severe hair loss, a score ≥2, in women that 
reported hair loss. On a severity scale of 1-4 for alopecia, 9.4%(23/246) of all women met 
this criterion for an alopecia classification. The highest prevalence of alopecia was in 
black or African American (26.9%, 7/26), East Asian (25%, 1/4), and mixed ethnicity 
(20%, 5/25) women. The mean population alopecia severity was 0.4±0.7 in the overall 
population and highest among East Asian (1±0.8) and Black women (0.8±1.1) (Table 11). 
Among women with PCOS (14.3%) the prevalence of alopecia was higher than in non-
PCOS women (7.9%)(Table 8). 
Table 11. Race/Ethnicity and Self-Reported Alopecia Severity. Patients reported 
alopecia severity from scale of 0-4 (0 being absent, 4 being severe) based on references 










































Total  0.4±0.7 9.4% 
(23/246) 
                  Race 
White  0.3±0.6 5.5% 
(9/165) 




Black or African American  0.8±1.1 26.9% 
(7/26) 
East Asian  1±0.8 25% (1/4) 
Southeast Asian 0.2±0.5 0% (0/5) 
South Asian  0.3±0.5 0% (0/6) 






 44 women consented to medical record validation (71%, 44/62) and 12 of those 
women had serum androgen levels on file. These 12 women had a total of 58 medical lab 
values for testosterone. The most recent lab values for bioavailable testosterone, free 
testosterone, and total testosterone are reported for analysis in Table 12. Total 
testosterone testing is done using LC-MS/MS by Quest Diagnostics and the reference 
range reported by Quest diagnostics is 2-45 ng/dL in females 18 years and older. Of the 
12 females with medical lab values, 33% (4/12) had total testosterone levels above this 
normal reference range. 
 
Table 12. PCOS diagnosis and serum levels for participants consenting to medical 
record review (n=58) 
 
 
 n  % or Mean ± SD (min, max) 
Self-Report   
Diagnosis of PCOS by Physician, % 48  
   Yes 12 25.0% 
   No  36 75.0% 
Self-Diagnosis of PCOS for participants not 
diagnosed by physician, % 36  
    Yes  2 5.6% 
    No 34 94.4% 
Medical Record Review   
Diagnosis of PCOS in Medical Record, % 46  
    Yes 11 23.9% 
    No 35 76.1% 
Serum lab values, Mean  ± SD **   
    Bioavailable Testosterone 11 10.9 ± 10.3 (1.0, 32.7) 
    Free Testosterone 11 5.4 ± 5.2 (0.5, 15.9) 
    Total  Testosterone 12 39.5 ± 27.9 (6.0, 87.0) 
*% missing (n): Diagnosis by physician: 17.2% (10); Diagnosis in medical record: 20.7% (12); Bioavailable 
testosterone: 81.0% (47); Free testosterone: 81.0% (47); Total testosterone: 79.3% (46);  






 The association between hyperandrogenism and polycystic ovary syndrome is 
well established (The Rotterdam ESHRE/ASRM, 2003). It is also well defined that 
androgen excess may manifest clinically as hirsutism, acne, alopecia, and other 
masculinization features. The Endocrine Society has indicated that androgen excess 
assessment is a key feature in diagnosing PCOS (The Rotterdam ESHRE/ASRM, 2003). 
Androgen excess is often validated by biochemical evaluation of serum TT, FT, DHEA-
S, and 17OHP (Lizneva et al., 2016). This study evaluated the distribution of self-
reported clinical signs of hyperandrogenism in a diverse, multi-ethnic cohort of women. 
Additionally, the study sought to determine differences between presentation of 
hirsutism, acne, and alopecia in women diagnosed with PCOS and those without a PCOS 
diagnosis. 
Androgen Excess and Demographics 
 It has been determined that there is ethnic variation in the presentation and 
manifestations of PCOS, particularly in the clinical presentation of hyperandrogenism 
(Bozdag et al., 2016). The pilot study data supports this claim as it demonstrated 
considerable ethnic variability in hirsutism, acne and alopecia. Based on mean total mFG 
score, South Asian women self-reported the greatest degree of hair growth, whereas East 
Asian women reported the lowest degree (Table 9). This observed ethnic variability in 
hair growth is due to the number of hair follicles per unit skin area and rate of hair growth 
(Yildiz, 2006). Furthermore, baseline hair distribution patterns vary between races. East 
Asian and Native American women have the least body hair. Whereas, White and 
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African-American women have an intermediate amount of hair and Mediterranean, South 
Asian, and Middle Eastern women have substantially more body hair than all other 
races/ethnicities (Barbieri & Ehrmann, 2018a; Monash University, 2018).  
 When considering the androgen excess marker of acne in the OM pilot, South 
Asian women self-reported the most severe cases (Table 10). Although studies have 
shown that the expression of acne differs between skin types, these studies are limited in 
establishing a clear pattern between race/ethnicity and acne caused by hyperandrogenism 
(Davis & Callender, 2010). There seemed to be an association between acne severity and 
race/ethnic variability in this study, however a larger study is needed to confirm these 
findings.  
 When evaluating the frequency of self-reported hair loss, African-American 
women had the highest number of alopecia cases when frequencies were compared to 
non-African American women (Table 11). This cohort data reveals that alopecia is an 
important indicator of androgen excess in African American women. Data presented at 
the 2016 American Academy of Dermatology’s 74th annual meeting demonstrated that 
African-American women are more prone to hair loss. There are thought to be three 
major types of alopecia in this population including: androgenic alopecia, central 
centrifugal cicatricial alopecia (CCCA), and traction alopecia. CCCA is caused by 
inflammation and destruction of hair follicles and traction alopecia occurs due to hair 
styling practices (American Academy of Dermatology, 2016). Despite identifying major 
types of alopecia, studies have not been able to determine how much of this hair loss is 
due to androgenic alopecia specifically.   
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Androgen Excess and PCOS 
 In the analysis of the pilot cohort data, hirsutism, acne, and alopecia were far 
more common among women diagnosed with PCOS than in non-PCOS women (Table 
8). This data supports the current understanding of hyperandrogenism as a criterion for 
PCOS diagnosis (The Rotterdam ESHRE/ASRM, 2003). Further data collection must be 
done in order to establish a relationship between biochemical hyperandrogenism as only 
33% of the participants that had their medical record validated had evidence of TT excess 
(Table 12). The small sample size makes it uncertain whether these values are 
representative of the pilot cohort, and the general population as a whole. Recruiting more 
participants willing to consent to medical record validation in the larger OM study will 
allow us to more appropriately validate the use of biochemical evidence for PCOS 
diagnosis.  
Strengths, limitations, and future considerations 
 The data from this paper was derived from a large multi-ethnic pilot cohort. This 
allowed for a representative evaluation of clinical hyperandrogenism in a more 
racially/ethnically diverse cohort of women than existing PCOS studies would have 
allowed. However, the study is limited by the subjective nature of asking participants to 
self-report hair growth, acne and hair loss. Including images for hair growth and hair loss 
along with the descriptors provided participants with a visual guide to help improve the 
accuracy of their response. Although Renee Cannon also illustrated images for acne, an 
executive decision was made not to include them in the questionnaire. It was believed 
that including the images would not have the same effect as it did for hirsutism and 
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alopecia responses. Instead clear descriptions were included with each acne type; past 
studies have shown that if subjects are given clear descriptions of acne type, they are 
capable of self-diagnosing their acne (Gold et al., 2009).  
 Although research findings have shown that hirsutism cutoffs are race/ethnicity 
dependent, the available literature is not representative of the scope of this variability. 
Furthermore, current studies may be biased since different regions, countries, or sample 
sizes may show different cutoffs in similar ethnicities. Conducting a larger study with an 
increased sample size and targeting race/ethnicities that are not currently represented in 
the pilot cohort may improve this issue. Additionally, despite the mFG scale being the 
most commonly used diagnostic tool for hirsutism, it has not been validated in patient 
populations for androgen excess self-assessment. Future studies should evaluate whether 
self-assessment of hair and skin using the mFG scale is consistent with clinical 
examination for the purposes of PCOS diagnosis. The information gathered would be 
used to inform physicians on how to diagnose and treat individuals with hirsutism and 
PCOS. 
 Similarly, there is a wide selection of more than 25 measures for acne available. 
However, most of these tools are subjective. One study evaluated 18 current acne global 
grading scales (AGGS) serving as a step towards harmonizing the scales and creating a 
foundation for the development of a universal grading scale (Tan et al., 2013). It is 
necessary to come up with a consistent universal standard for grading acne severity in 
order to strengthen the use of acne as a diagnostic feature for hyperandrogenism. 
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 In order to have a more diverse and accurate representation of the global 
population, the OM survey can be translated into different languages and more targeted 
recruitment efforts can be made. Preliminary steps have been made in making these 
changes as Dr. Shruthi Mahalingaiah’s Lab has started translating the questionnaire into 
Spanish in order to expand accessibility to Spanish speakers.  Having a large cohort 
representative of a global population will increase our understanding on the presentation 






Questionnaire from Ovulation and Menstruation (OM) Study Pilot Survey  
 
Medical record validation   
 
Section III: About you 
10. Have you ever received care at Boston Medical Center?  
a. Yes  
b. No  
11. We would like to look at your medical records in order to study other factors 
associated with menstrual health. All study data is protected by HIPAA-compliant 
equipment and software.   
a. Yes, it is OK to check my medical record  




Section IV: Baseline Questionnaire 
4. Which categories describe you? Select all that apply. You may select more than 
one group.  
a. White   
For example, German Irish, English, Italian  
b. Hispanic, Latina, or Spanish Origin   
For example, Mexican, Mexican American, Puerto Rican, Cuban, 
Salvadoran, Dominican, Colombian, etc  
c. Black or African American  
For example, African American, Jamaican, Haitian, Nigerian, 
Ethiopian, Somali, etc.  
d. East Asian   
For example, Chinese, Japanese, Korean, Mongolian, Taiwanese, etc.  
e. Southeast Asian   
For example, Burmese, Cambodia, Hmong, Indonesian, Laotian, 
Malaysian, Filipino, Thai, Vietnamese, etc.  
f. South Asian   
For example Asian Indian, Bangladeshi, Bhutanese, Maldivian, Nepalese, 
Pakistani, Sri Lankan, etc.   
g. American Indian or Alaskan Native  
For example, Navajo Nation, Blackfeet Tribe, Mayan, Aztec, Native 
Village of Barrow Inupiat Traditional Government, Nome Eskimo 
Community, etc.  
h. Middle Eastern or North African  




i. Native Hawaiian or Other Pacific Islander  
For example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, 
Marshallese, etc.  




Section VII: Contraceptive History   
1. Hormonal contraceptives include the Pill, patch, implants, or injectables. Have 
you ever used hormonal contraceptives?  
a. Yes   
b. No 
 
Androgen Excess Questions 
 
Section VIII: Health and Body 
5. Thinking about your face or back, how would you rate your acne? If your acne 
changes during menstrual cycle, please think about the acne at its worst.  
a. None or rare acne (none to a couple pimples)  
b. Mild acne (4 or more pimples)  
c. Moderate acne (4 or more pimples that are red and irritated)  
d. Severe acne (4 or more pimples that are red, irritated, and have pus)  
 
For the next questions, we want to know about how much coarse or thick hair you have 
on different parts of your body. When you answer, please think about your natural body 
state – that means how much hair you have when you are not using hair removal 
procedures or treatment. You can use the images as a guide, but remember your own hair 
pattern may be slightly different.:  
13. How much coarse or thick hair do you have on your upper lip?  
  [Upper Lip hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
14. How much coarse or thick hair do you have on your chin?  
 [Chin hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
15. How much coarse or thick hair do you have on your chest and nipple area? 
[Chest and Nipple hair growth image included] 
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a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
16. How much coarse or thick hair do you have on your upper abdomen? 
 [Upper abdomen hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
17. How much coarse or thick hair do you have on your lower abdomen – that is the 
area from your belly button to your pubic area? 
 [Lower abdomen hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
18. How much coarse or thick hair do you have on your upper arms? 
 [Upper arms hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
19. How much coarse or thick hair do you have on your thighs? 
 [Thighs hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
20. How much coarse or thick hair do you have on your back? 
 [Back hair growth image included] 
a. 0 No thick hairs  
b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
21. How much coarse or thick hair do you have on your buttocks? 
 [Buttocks hair growth image included] 
a. 0 No thick hairs  
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b. 1 Few scattered thick hairs  
c. 2 several scattered thick hairs  
d. 3 moderate amount of thick hairs  
e. 4 A lot of hair  
22. Using the images below, how would you rate your current scalp hair thickness? 
You can use the images as a guide, but your own hair pattern may be slightly 
different. [Scalp hair loss image included] 
a. 0 Thick and full hair  
b. 1 Slightly reduced hair with widening part  
c. 2 Reduced hair with widening part and some scalp showing  
d. 3 Significantly reduced hair and more scalp showing  
e. 4 Scalp mostly visible    
  
Polycystic Ovary Syndrome Questions 
Section IX: Polycystic Ovary Syndrome  
1. Polycystic Ovary Syndrome is a health condition involving irregular 
periods, excess testosterone, increased acne, body and facial hair, 
and many small cysts in the ovaries. Some women also experience hair loss on the 
scalp. Has a doctor ever diagnosed you with Polycystic Ovary Syndrome or PCOS?  
a. Yes 
b. No    
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